News | April 07, 2022
BIO KOREA, Asia's Biggest Bio-Health Convention, to open in May 2022
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It also secures US $ 10 million for US launch and commercialization
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Subscribe To Our Newsletter & Stay Updated
